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Abstract
Background: As chondrosarcomas are resistant to chemotherapy and ionizing radiation, therapeutic options are
limited. Radical surgery often cannot be performed. Therefore, additional therapies such as antiangiogenesis represent a
promising strategy for overcoming limitations in chondrosarcoma therapy. There is strong experimental evidence that
SU6668, an inhibitor of the angiogenic tyrosine kinases Flk-1/KDR, PDGFRbeta and FGFR1 can induce growth inhibition
of various primary tumors. However, the effectiveness of SU6668 on malignant primary bone tumors such as
chondrosarcomas has been rarely investigated. Therefore, the aim of this study was to investigate the effects of SU6668
on chondrosarcoma growth, angiogenesis and microcirculation in vivo.
Methods: In 10 male severe combined immunodeficient (SCID) mice, pieces of SW1353 chondrosarcomas were
implanted into a cranial window preparation where the calvaria serves as the site for the orthotopic implantation of bone
tumors. From day 7 after tumor implantation, five animals were treated with SU6668 (250 mg/kg body weight, s.c.) at
intervals of 48 hours (SU6668), and five animals with the equivalent amount of the CMC-based vehicle (Control).
Angiogenesis, microcirculation, and growth of SW 1353 tumors were analyzed by means of intravital microscopy.
Results: SU6668 induced a growth arrest of chondrosarcomas within 7 days after the initiation of the treatment.
Compared to Controls, SU6668 decreased functional vessel density and tumor size, respectively, by 37% and 53% on
day 28 after tumor implantation. The time course of the experiments demonstrated that the impact on angiogenesis
preceded the anti-tumor effect. Histological and immunohistochemical results confirmed the intravital microscopy
findings.
Conclusion: SU6668 is a potent inhibitor of chondrosarcoma tumor growth in vivo. This effect appears to be induced
by the antiangiogenic effects of SU6668, which are mediated by the inhibition of the key angiogenic receptor tyrosine
kinases Flk-1/KDR, PDGFRbeta and FGFR1. The experimental data obtained provide rationale to further develop the
strategy of the use of the angiogenesis inhibitor SU6668 in the treatment of chondrosarcomas in addition to established
therapies such as surgery.
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Background
Chondrosarcomas are the second most frequent malig-
nant primary bone tumors in humans and are usually
resistant to ionizing radiation and chemotherapy. To date,
the only curative therapy is the surgical resection provided
that an R0-situation can be achieved and metastases do
not exist at the time of the diagnosis.
Due to the knowledge that a solid tumor cannot grow
beyond a critical size of 1–2 mm3 or metastasize without
an adequate blood supply [1,2], therapeutic strategies tar-
geting tumor vasculature, i.e. antiangiogenic therapies,
represent a promising therapeutic option in addition to
established therapies. Cells from the tumor vasculature
are generally non-transformed and less prone to acquiring
drug resistance [3]. Therefore, endothelial processes are
considered as ideal targets for the prevention and control
of tumor growth [4]. The idea of inhibiting tumor neovas-
cularization without causing negative side-effects in the
host vascular system is based further on the observation
that the vasculature in normal adults is generally quies-
cent, with only 0.01% of endothelial cells undergoing cell
division at any given time. Regarding tumor vasculature,
the fraction of cycling endothelial cells may be 2–3 orders
of magnitude higher. Thus, agents that antagonize active
signal transduction are likely to have a minimal effect on
the normal vasculature and therefore allow a more tar-
geted approach regarding proliferating tumor vessels [5].
In principle, antiangiogenic therapy is applicable on any
tumor entity, as endothelial cells represent a common cell
type of all solid tumors [4]. Substances inhibiting active
signal transduction of the angiogenic cascade, such as
inhibitors of the receptor tyrosine kinases, have shown
promising antiangiogenic effects in preclinical settings if
administered as single agents or in combination with
established therapies such as chemotherapy and radiation
[6-12].
SU6668 is a small-molecule inhibitor of the receptor tyro-
sine kinases Flk-1/KDR (vascular endothelial growth fac-
tor receptor 2, VEGR2), PDGFRbeta (platelet-derived
growth factor receptor beta) and FGFR1 (fibroblast
growth factor receptor 1), which play an important role in
angiogenesis, as they transduce the signals of the key ang-
iogenic growth factors VEGF, PDGF and bFGF. Due to this
mechanism, SU6668 is considered to be a potent sub-
stance for antagonizing central pathways of angiogenic
signal transduction. The substance has shown promising
antiangiogenic effects on primary tumors such as colon
and lung carcinomas [9-12]. However, studies on the ther-
apeutic efficiency of receptor tyrosine kinase inhibitors
such as SU6668 on primary bone tumors are very rare
[13]. The aim of the present study, therefore, was to inves-
tigate the in vivo effects of SU6668 on growth, angiogen-
esis and microcirculation of chondrosarcomas by means
of intravital microscopy.
Methods
Animal model and cell lines
Experiments were performed on 10 adult male severe
combined immuno deficient mice (SCID, C.B-17/IcrCrl-
scid-BR, Charles River Laboratories Inc., Sulzfeld, Ger-
many, 7 to 8 weeks old, 20 to 25 g body weight), follow-
ing institutional guidelines approved by the local animal
review board. All surgical procedures were performed in
strictly aseptic conditions within a laminar flow unit
(Merck Eurolab, Bruchsal, Germany) under deep anesthe-
sia by an intra peritoneal injection of a mixture of keta-
mine (Ketanest®, 65 mg/kg body weight, Pfizer, Karlsruhe,
Germany), xylazine (Rompun®, 13 mg/kg body weight,
Bayer, Leverkusen, Germany) and acepromazine (Sedast-
ress®, 2 mg/kg body weight, Medistar, Holzwickede, Ger-
many).
The human chondrosarcoma cell line SW 1353 was
obtained from ATCC (HTB-94, LGC Promochem GmbH,
Wesel, Germany). Tumor cells [1 × 107/ml] were injected
subcutaneously into the left flank of each donor mouse
and grown to a volume of 0.5 to 1.0 cm3. After sacrificing
the donor mouse, the tumor was excised, cut into small
chunks (volume 0.5–1.0 mm3) in Dulbecos Modified
Eagle's Medium (DMEM,) at 4°C, and implanted into the
recipient mouse in the following manner:
Surgical preparation of the cranial window was performed
as described in detail elsewhere [14]. Briefly described, the
scalp of the mouse was shaved and surgically excised in an
oval area to expose the frontal and parietal bone. The peri-
osteum was removed and an oval cavity of approximately
2 by 1 by 0.5 mm was milled into the calvaria by eliminat-
ing parts of the external tabula of the calvaria including
the spongious bone underneath. Then one small chunk
(approx. 0.5–1.0 mm3) of the human chondrosarcoma
SW 1353 was implanted into the cavity. To prevent dehy-
dration or mechanical damage to the tumors, the prepara-
tion was sealed with a glass cover slip and bone cement
made of a mixture of ethyl cyanoacrylate glue (Pattex®
Blitz Kleber, Henkel, Germany) and GC Ostron®-Powder
(methyl methacrylate polymer, GC Europe, Belgium).
The animals were housed individually in special filter
cages to maintain aseptic conditions and to prevent
mutual damage to the cranial window. The animals were
provided with sterile standard pellet food and water ad
libitum.
SU6668 treatment
SU6668 was provided by Sugen Inc. (San Francisco, Cali-
fornia, USA) and was dissolved in a carboxymethylcellu-BMC Cancer 2007, 7:49 http://www.biomedcentral.com/1471-2407/7/49
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lose (CMC)-based vehicle at 50 mg SU6668 per ml
vehicle. Five animals each were treated by subcutaneous
injection of 250 mg/kg body weight SU6668 (SU6668, n
= 5) or the equivalent amount of the (CMC)-based vehicle
alone (Control, n = 5) every 48 hours. The chosen SU6668
dosage is in accordance with the dosages for animal trials
reported in the literature and represents the lower range of
dosages that were shown to be effective against primary
tumors [9,10,13,15,16]. Treatment started on day 7 after
tumor implantation and continued until termination of
the experiments on day 28 after tumor implantation.
Intravital microscopy
For intravital microscopy, mice were anesthetized and
positioned on a custom made stereotactic device.
In the first week after tumor implantation, mice were
investigated daily under epi-illumination with a stereotac-
tic microscope (Leica MZ75, Leica, Germany) employing a
5 to 40 fold magnification. At 24-hour intervals, the first
appearance of (i) hemorrhage, (ii) the first appearance of
newly formed blood vessels entering the implanted tumor
tissue, and (iii) the onset of perfusion in these newly
formed vessels were determined.
Intravital fluorescence video microscopy was performed
using an epi-illumination fluorescence microscope unit
(Leica, Germany) equipped with a 4x (EF 4/0.12, Leitz,
Wetzlar, Germany) and 40x (Zeiss Achroplan 40x/0.75 w,
Carl Zeiss, Germany) objective on days 7, 14, 21, and 28
after tumor implantation. For off line analysis, regions of
interest were recorded on video tapes using a S-VHS vide-
ocassette recorder (AG-7350, Panasonic, Japan) at a rate
of 50 frames/s and a digital camera (Kappa CF 8/1, Kappa
Opto-electronics, Germany).
Using an adequate fluorescence filter set for green light
(bandpass 515–560 nm), the intravenous injection of the
plasma marker fluorescein isothiocyanate (FITC)-labeled
dextran (Sigma, St. Louis, MO, FITC-Dextran, FD 2000S,
molecular weight 2.000.000; 0.1 ml of a 5% solution in
0.9% NaCl) enabled the observation of tumor microcircu-
lation.
Off-line analysis of tumor growth and microhemodynamics
Tumor growth was determined off-line by measuring its
two-dimensional surface area in mm2 from standardized
digital photographs of the cranial window preparation at
10-fold magnification on days 7, 14, 21, and 28 after
implantation using a computer-based analysis program
(AnalySIS®  V3.0, Soft Imaging System, Münster, Ger-
many).
The functional microvessel density (FVD) was determined
as the length of all perfused microvessels within a tumor
in relation to the two-dimensional surface area of the
tumor in mm/mm2 indicated by the fluorescence of FITC-
labeled dextran in all perfused vessels. Recordings on
video tape for off-line analysis of the FVD were made for
15s, each. Off-line analysis was performed using a compu-
ter-based image analysis program (CapImage®, Engineer-
ing Office Dr. Zeintl, Heidelberg, Germany).
Histopathologic and immunohistochemical assessment
The mice were sacrificed on day 28 after tumor implanta-
tion and the tumors were immediately excised along with
the surrounding tissue of the calvaria and the brain for
further histopathologic and immunohistochemical inves-
tigations. Tissue samples were fixed for 24–48 hours by
immersion in 4% formalin solution. After decalcification
of the bone in ethylene-diaminetetraacetic acid for 2
weeks, samples were embedded in paraffin and sliced into
three-μm serial sections for Hematoxylin-Eosin staining
and five-μm serial sections for immunohistochemistry.
To identify endothelial cells, immunohistochemistry for
CD31 (PECAM-1) was performed. After deparaffiniza-
tion, sections were pretreated with Retrievagen A® solution
(Cat. No. 550524, BD Pharmingen, Basel, Switzerland)
for antigen retrieval at 90°C for 10 minutes. Tissue sec-
tions were placed into 0.3% H202 in tris buffered saline
(TBS) and 100% goat serum afterwards to block endog-
enous peroxidase and unspecific binding, respectively.
Tissue samples were incubated overnight at 4°C with the
primary antibody for CD31 (anti-mouse CD31 from rat,
Cat. No. 550274, BD Pharmingen, Basel, Switzerland) or
with mouse IgG for negative controls. Subsequently, the
secondary antibody (biotinylated anti-rat IgG from goat,
1:1000, Cat. No. RPN1005, Amersham Biosciences, Otelf-
ingen, Switzerland) and Streptavidin-horadish peroxidase
conjugate (Cat. No. RPN1231, Amersham Biosciences,
Otelfingen, Switzerland) were applied to the sections. Sec-
tions were then stained with 3-Amino-9-ethylcarbazole
substrate (AEC, Cat. No. A6926, Sigma, Buchs, Switzer-
land), counterstained with hematoxylin and mounted
with AquaTex.
Statistics
All numerical data are presented as median with 25% and
75% quartiles. Using the software program SigmaStat® for
Windows (Version 2.03, SPSS, Chicago, IL), data were
analyzed statistically. The Mann-Whitney rank sum test
was applied for pair wise comparison procedures. Differ-
ences were considered significant at p < 0.05.
Results
The first newly formed vessels in all tumors were observed
6 days after implantation. Vessel formation was followed
by a rapid onset of perfusion within 24 hours. IntravitalBMC Cancer 2007, 7:49 http://www.biomedcentral.com/1471-2407/7/49
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microscopy showed that the origin of angiogenic sprout-
ing was from vessels located within the surrounding bone.
In Controls, functional vessel density (FVD) increased
between day 7 and day 14 after tumor implantation,
reaching a constant plateau between days 14 and 28 (Fig.
1a). After the initiation of therapy on day 7 after tumor
implantation, FVD continuously decreased over the
period of investigation with SU6668 (day 28: 5.5 mm/
mm2 (5.1/6.3) vs. day 7: 7.8 mm/mm2 (6.7/8.3); Fig. 1a).
On day 28 after tumor implantation, FVD was signifi-
cantly smaller with SU6668 compared to Controls (5.5
mm/mm2 (5.1/6.3) vs. 8.6 mm/mm2 (8.1/8.9); Fig. 1a).
Tumor growth was identical in all animals until day 7
after tumor implantation. In Controls, the two-dimen-
A: Functional vessel density, time course Figure 1
A: Functional vessel density, time course. Y-axis: functional vessel density (FVD in mm/mm2), x-axis: time in days after tumor 
implantation. SU6668 induced a regression of functional vessel density (FVD), while FVD in Controls increased between day 7 
and 14 after tumor implantation, remaining constant thereafter. B: Tumor surface, time course. Y-axis: tumor surface (ATUM in 
mm2), x-axis: time in days after tumor implantation. In Controls, tumor surface continuously increased over the period of 
investigation. In contrast to this, SU6668 induced a growth arrest of chondrosarcomas beginning on day 14 after tumor implan-
tation. A and B: Treatment started on day 7 after tumor implantation. Results are given as median with 25% quartiles and 75 
% quartiles. Mann-Whitney rank sum test, #p < 0.05 versus Control, *p < 0.05 versus day 7 after tumor implantation. C and 
D: Immunohistochemistry for CD31 (PECAM-1) on day 28 after tumor implantation confirmed the results of the in vivo quan-
tification of the functional vessel density with intravital microscopy. Untreated Controls showed uniformly distributed CD31 
positive cells (brown) within the implanted tumors (C). In SU6668 treated tumors, CD31 positive cells were rare and only 
detectable in peripheral areas of the tumor residues (D). Scale bars represent 50 μm.BMC Cancer 2007, 7:49 http://www.biomedcentral.com/1471-2407/7/49
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sional tumor surface (ATum) continuously increased over
the period of investigation reaching 5.3 mm2 (4.4/7.2) on
day 28 after tumor implantation (Fig. 1b). After initiation
of the treatment on day 7 after tumor implantation, in
SU6668 ATum increased until day 14 after tumor implanta-
tion. Subsequently to day 14 after tumor implantation, a
growth arrest of chondrosarcomas occurred in SU6668.
On day 28 after tumor implantation, the ATum was 2.5
mm2 (1.9/3.4) in SU6668, thus being statistically smaller
than in Controls, where ATum was 5.3 mm2 (4.4/7.2; Fig.
1b).
The comparison of the time courses of FVD and ATum dem-
onstrated that in SU6668, ATum had still increased in the
first week after therapy initiation, while FVD was already
regressive over the same time period of investigation.
Histologically, typical signs of a malignant tumor were
observed in Controls on day 28 after tumor implantation.
In accordance to in vivo findings, the volume of chondro-
sarcomas increased significantly compared to the small
chunks (volume 0.5–1.0 mm3) that were initially
implanted (Fig. 2a). Large tumor masses had grown
above, below, and into the calvaria. Histology revealed
extensive infiltration and resorption of the adjoining
bone as signs for typical growth behavior of malignant
tumors. However, infiltration into the underlying brain
was not observed on day 28 after tumor implantation
(Fig. 2a–c). In contrast to this, the volume of chondrosar-
comas in SU6668 remained at a much smaller level com-
pared to Controls. Furthermore, tumors showed signs of
regression in SU6668. On day 28 after tumor implanta-
tion, there was not one large formation of any solid
tumor, but residual chondrosarcoma cells were observed
embedded in fibrous tissue that filled large parts of the
cranial window preparation (Fig. 2d–f). In regions of pre-
vious bone resorption, regenerative bone formation was
observed (Fig. 2e). The immunohistochemical staining of
endothelial cells confirmed the results of the in vivo quan-
tification of the functional vessel density with intravital
microscopy. Untreated tumors showed uniformly distrib-
uted CD31 positive endothelial cells. In contrast, tumors
which were treated with SU6668 were only weekly posi-
tive for CD31 (Fig. 1c–d).
Injections of SU6668 or of the CMC-vehicle alone were
well tolerated, as no differences in animal behavior or loss
of weight were observed.
Discussion
Due to the insufficient response of chondrosarcomas to
chemotherapy and ionizing radiation, current curative
therapy of these tumors is usually limited to surgery. As
angiogenesis is essential for tumor growth, the selective
destruction of tumor feeding and draining blood vessels
represents a promising strategy for overcoming the thera-
peutic limitations of malignant primary bone tumors.
The small molecule receptor tyrosine kinase inhibitor
SU6668 was used as an antiangiogenic agent against the
human chondrosarcoma SW1353, which was grown in a
cranial window preparation in SCID mice. SU6668 medi-
ates the simultaneous inhibition of the receptor-tyrosine
kinase activity of vascular endothelial growth factor
(VEGF), fibroblast growth factor (FGF), and platelet-
derived growth factor (PDGF), which are key mediators of
tumor angiogenesis [9,15,17-19]. SU6668 has already
shown encouraging antiangiogenic effects on some solid
tumors [9-11]. However, the effects of SU6668 on primary
bone tumors have only been described once for Ewing's
sarcoma family tumors [13].
The present data demonstrate the effective anti-tumor
action of SU6668. Treatment of SW1353 chondrosarco-
mas with SU6668 at 250 mg/kg/48 h decreased the tumor
size to 53% of the size in Controls on day 28 after tumor
implantation. The time course of two-dimensional tumor
surfaces demonstrated that only SU6668 induced a
growth arrest of tumors starting on day 14 after tumor
implantation. In Controls, at the same time a continuous
increase of the tumor size was measured. The in vivo find-
ings were confirmed by histology from tissues excised on
day 28 after tumor implantation. In Controls, typical
signs of the behavior of malignant tumor growth were
observed while SU6668 treatment resulted in small resid-
ual tumors with the formation of scar tissue within the
tumor. These results are consistent with previous findings
on growth inhibition of tumor xenografts by SU6668:
Laird et al. [15] found a slight increase in volumes of the
human epidermoid tumor xenograft A431 within the first
week after initiation of SU6668 treatment resulting in a
growth arrest of these tumors thereafter. Marzola et al.
[10] described a 60% growth inhibition of HT-29 colon
carcinomas treated with SU6668 compared to untreated
Controls.
The anti-tumor activity of SU6668 has been attributed to
its antiangiogenic potential arising from its inhibitory
effect on the receptor-tyrosine kinase activity of VEGF,
FGF, and PDGF. Inhibition of the downstream action of
these angiogenic receptors has been shown to induce
endothelial cell apoptosis [9,20]. Furthermore, Laird et al.
[9] showed that endothelial cell apoptosis preceded
tumor cell apoptosis. The authors concluded that SU6668
treatment initiates vessel death by apoptosis, which in
turn leads to subsequent tumor cell death. In the present
study, SU6668 significantly reduced functional vessel
density of tumors by 37% compared to Controls, demon-
strating the antiangiogenic potential of SU6668. A com-
parison of the time courses of functional vessel densityBMC Cancer 2007, 7:49 http://www.biomedcentral.com/1471-2407/7/49
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and tumor size demonstrated that SU6668 primarily
induced a reduction in tumor vascularization directly after
initiation of this therapy. This was followed by growth
arrest of the implanted chondrosarcomas starting on day
14 after tumor implantation. In accordance with findings
by Laird et al. [9], and analogous to findings from a previ-
ous study where Celecoxib-induced inhibition of the
functional vessel density caused a reduced growth of the
lung carcinoma A 549 implanted into a cranial window
preparation [21], we conclude that an underlying mecha-
nism of the anti-tumor effect of SU6668 is the antiang-
iogenic potential resulting in a reduction in blood vessels
that feed and drain tumors, which in turn halts tumor pro-
gression.
SW 1353 chondrosarcoma at day 28 after tumor implantation, hematoxylin-eosin stained cross section from representative tis- sue samples of the cranial window preparation Figure 2
SW 1353 chondrosarcoma at day 28 after tumor implantation, hematoxylin-eosin stained cross section from representative tis-
sue samples of the cranial window preparation. A, D: 4-fold magnification, scale bar 500 μm. B, C, E, F: 20-fold magnification, 
scale bar 100 μm. In Controls, the overview magnification shows a large tumor formation with high cellular density (A). 
Enlarged cutaway views (B, C) from the framed regions show high cellular density and destructive tumor growth with resorp-
tion of the surrounding bone (arrows, tips pointing to resorption lacunae). In SU6668, tumor size was markedly reduced (D). 
Enlarged cutaway views (E, F) from the framed regions show fibrous "scar" tissue with residual tumor cells and low cellular 
density and regenerative bone formation at sites of previous bone resorption (double arrows, distal tip pointing to former 
resorption front, proximal tip pointing to new mineralization front).BMC Cancer 2007, 7:49 http://www.biomedcentral.com/1471-2407/7/49
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Although the tumor vasculature is thought to be little
prone to acquiring drug resistance [3,22,23] recurrence of
tumor growth after an initial period of suppression during
long-term antiangiogenic therapy has also been described
[24-26]. Acquired drug resistance has predominantly been
described for drugs only interfering with a single ang-
iogenic pathway [24-26]. As SU6668 does not target just
one signaling pathway but inhibits signal transduction
through the growth factor receptors VEGFR2, PDGFb2
and FGFR1, drug resistance is less likely to occur [24].
Conclusion
The data presented demonstrate that SU6668 is a potent
inhibitor of tumor growth of chondrosarcomas in vivo.
The anti-tumor effects can be attributed to the antiang-
iogenic effects of the substance, which are mediated by the
inhibition of the receptor tyrosine kinases Flk-1/KDR
(VEGR2), PDGFRbeta and FGFR1. Antiangiogenic therapy
using the application of SU6668 appears to be a promis-
ing way to expand the therapeutic options in chondrosar-
coma therapy. However, long-term studies must be
performed to elucidate the effects of a long-term treat-
ment such as potential side effects, the development of
drug resistance or relapse of tumor growth.
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